45 SIDNEY STREET, CAMBRIDGE, MA
Contingent Value Rights Agreement
Shareholder votes
To Acquire, Expanding Portfolio in Rare Immunological Disease and Adding Early-Stage Pipeline in Immunology
Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Results
Reg. FD
Investor Presentation
Q1
FY 2023
Q3
Q2
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS